MIGUEL
ARRABAL MARTÍN
PROFESOR TITULAR DE UNIVERSIDAD
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (4)
2024
-
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 994-1000
-
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study
European Journal of Cancer, Vol. 196
2023
-
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177
-
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5118-5130